ChitogenX Inc. (CNSX: CHGX)
Health Care · Biotechnology · CA
CA$—
— today · — 1Y
ChitogenX Inc. (CNSX: CHGX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $303.81K.
trading between 0.01 and 0.05.
Tweenvest scores ChitogenX Inc. across four factors: quality 4/100. Its strongest factor is quality.
CHGX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $303.81K
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.02
- Dividend yield
- —
- Beta (5Y)
- -2.09
- 52-week high
- CA$0.05
- 52-week low
- CA$0.01
- Avg volume (3M)
- —
- Shares outstanding
- 83.13M
- Employees
- —
- Next earnings
- —
About ChitogenX Inc.
ChitogenX Inc. is a Canadian biologics firm specializing in orthopaedic and sports medicine. The company is dedicated to the research and development of innovative therapeutic technologies designed to improve the success rates of soft tissue repair in sports medicine surgeries. Its product pipeline features several biomaterial-based treatments, including Ortho-R for rotator cuff repair, Ortho-M for meniscus repair, and Ortho-C for articular cartilage repair. Additionally, they are developing Ortho-V to address osteoarthritis healing and ORTHO-T for tendon regeneration. Established in 2015, the company underwent a name change from Ortho Regenerative Technologies Inc. to ChitogenX Inc. in September 2022. It maintains its headquarters in Kirkland, Canada.
- ISIN
- CA1699161032
- Founded
- 2015
- Listed since
- Oct 10, 2017
- Exchange
- Canadian National Stock Exchange
- Currency
- CAD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.41 | -0.04% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $445.03 | +0.27% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €874.40 | +1.18% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.54 | +1.91% |
Figures last refreshed Aug 18, 2026.